Array Biopharma (ARRY) Says FDA Accepted Binimetinib NDA as Advanced NRAS-Mutant Melanoma Treatment
Go back to Array Biopharma (ARRY) Says FDA Accepted Binimetinib NDA as Advanced NRAS-Mutant Melanoma Treatment| Array Biopharma, Inc. (NASDAQ: ARRY) | Delayed: 12.23 +0.29 (2.43%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $11.94 | 52 Week High | $7.27 | |||
| Open | $11.87 | 52 Week Low | $2.39 | |||
| Day High | $12.28 | P/E | N/A | |||
| Day Low | $11.60 | EPS | $-0.61 | |||
| Volume | 5,425,408 | |||||
